Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.47817
S. Örnek, A. Bilgic, Serkan Yazici, D. Bayramgürler, H. Şanli, N. Onsun
Coronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group of immune system neoplasms, which are subclassified as indolent and aggressive types according to their survival rates. PCL treatment ranges from skin-based therapies to systemic treatments, of which immunosuppressive effects occur in some. During the COVID-19 pandemic, patients with PCL should be protected from possible COVID-19 complications, and the optimal treatment should be provided to control the disease taking into account the treatment-related risks. Therefore, recommendations about the management of patients with PCL during the COVID-19 pandemic were overviewed in light of the literature. Topical treatments can generally be considered low-risk therapies and can be continued without interruption. Phototherapy, skin radiotherapy, and total skin electron beam therapy increase the risk of COVID-19 exposure due to hospital visits. Moderate-risk therapies like interferons, systemic retinoids, methotrexate, and systemic corticosteroids might be used with caution. Advanced-stage patients with COVID-19 related comorbidity and who previously received immunosuppressive therapy should be carefully evaluated. Biological agents and systemic chemotherapeutics, which are considered high-risk, should not be delayed when needed. However, increasing intervals between treatments or switching to alternative therapies may be preferable in stable diseases. Most importantly, all patients with PCL should be ensured to comply with general protection measures as long as the pandemic continues.
{"title":"Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic","authors":"S. Örnek, A. Bilgic, Serkan Yazici, D. Bayramgürler, H. Şanli, N. Onsun","doi":"10.4274/turkderm.galenos.2021.47817","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.47817","url":null,"abstract":"Coronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group of immune system neoplasms, which are subclassified as indolent and aggressive types according to their survival rates. PCL treatment ranges from skin-based therapies to systemic treatments, of which immunosuppressive effects occur in some. During the COVID-19 pandemic, patients with PCL should be protected from possible COVID-19 complications, and the optimal treatment should be provided to control the disease taking into account the treatment-related risks. Therefore, recommendations about the management of patients with PCL during the COVID-19 pandemic were overviewed in light of the literature. Topical treatments can generally be considered low-risk therapies and can be continued without interruption. Phototherapy, skin radiotherapy, and total skin electron beam therapy increase the risk of COVID-19 exposure due to hospital visits. Moderate-risk therapies like interferons, systemic retinoids, methotrexate, and systemic corticosteroids might be used with caution. Advanced-stage patients with COVID-19 related comorbidity and who previously received immunosuppressive therapy should be carefully evaluated. Biological agents and systemic chemotherapeutics, which are considered high-risk, should not be delayed when needed. However, increasing intervals between treatments or switching to alternative therapies may be preferable in stable diseases. Most importantly, all patients with PCL should be ensured to comply with general protection measures as long as the pandemic continues.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45967622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.33339
E. Çalışkan, A. Botsalı
The word laser is an acronym for “light amplification by stimulated emission of radiation.” Throughout the past halfcentury, the better understanding of cutaneous physiology and laser technology has substantially improved to provide a sophisticated perspective for laser-skin interactions. Basic knowledge of the fundamentals of laser physics is essential to understanding laser devices. Ablative lasers lead to the controlled removal of the outer layer of the skin along with various degrees of heat formation within the dermis. Ablative lasers have proven efficacy for skin rejuvenation hence commonly used in aesthetic dermatology. Additionally, they are increasingly implemented into medical dermatology for various skin disorders' management. This study aimed to reveal the basic information in using ablative lasers and illustrate the numerous indications based on the physician’s creative potential. The theory of “selective photo-thermolysis” of Anderson and Parish in 1983 is a mile-stone for laser physics. According to this theory, thermal damage can be confined to a selected target within the exposed tissue. This target is determined by laser device wavelength and may include hemoglobin, melanin, exogenous pigment, or water. The target chromophore of ablative lasers is water. Three criteria must be fulfilled to sustain a pure ablation effect during laser applications and eliminate heat generation within the tissue. First, the target chromophore (water) must more avidly absorb the given wavelength than the surrounding tissue. Second, the duration of laser exposure (pulse duration) must be less than the thermal relaxation time of the exposed tissue. Third, laser procedures must be applied with sufficient high-energy settings to yield ablation. The ablative lasers in dermatologic practice include carbon dioxide (CO 2 ) and Erbium:yttrium-aluminum-garnet (Er:YAG) lasers, which emit light in the infrared spectrum. The exposed tissue rapidly heats due to the preferential absorption of energy by intracellular water, which leads to vaporization. The wavelength of the Er:YAG laser (2940 nm) is closer to the absorption peak of water (3000 nm) compared to that of the CO 2 laser (10,600 nm). Consequently, during Er:YAG laser applications, almost all energy is absorbed in the epidermis and papillary dermis, yielding superficial ablation with less accompanying thermal tissue damage and thermocoagulation. Contrarily, heat generation and coagulation are prominent features of CO 2 laser applications. Extreme heat generation is avoided during ablative laser surgeries to diminish ominous long-term complications, such as postinflammatory hyperpigmentation and scarring. However, heat generation can be beneficial and/or are required for certain conditions since the thermal effect stimulates collagen production and provides hemostasis. Conventional Er:YAG lasers lead to almost pure ablation with minimal thermal damage; however, coagulation can be acquired to a certain degr
{"title":"How to perform ablative laser surgery for skin resurfacing?","authors":"E. Çalışkan, A. Botsalı","doi":"10.4274/turkderm.galenos.2021.33339","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.33339","url":null,"abstract":"The word laser is an acronym for “light amplification by stimulated emission of radiation.” Throughout the past halfcentury, the better understanding of cutaneous physiology and laser technology has substantially improved to provide a sophisticated perspective for laser-skin interactions. Basic knowledge of the fundamentals of laser physics is essential to understanding laser devices. Ablative lasers lead to the controlled removal of the outer layer of the skin along with various degrees of heat formation within the dermis. Ablative lasers have proven efficacy for skin rejuvenation hence commonly used in aesthetic dermatology. Additionally, they are increasingly implemented into medical dermatology for various skin disorders' management. This study aimed to reveal the basic information in using ablative lasers and illustrate the numerous indications based on the physician’s creative potential. The theory of “selective photo-thermolysis” of Anderson and Parish in 1983 is a mile-stone for laser physics. According to this theory, thermal damage can be confined to a selected target within the exposed tissue. This target is determined by laser device wavelength and may include hemoglobin, melanin, exogenous pigment, or water. The target chromophore of ablative lasers is water. Three criteria must be fulfilled to sustain a pure ablation effect during laser applications and eliminate heat generation within the tissue. First, the target chromophore (water) must more avidly absorb the given wavelength than the surrounding tissue. Second, the duration of laser exposure (pulse duration) must be less than the thermal relaxation time of the exposed tissue. Third, laser procedures must be applied with sufficient high-energy settings to yield ablation. The ablative lasers in dermatologic practice include carbon dioxide (CO 2 ) and Erbium:yttrium-aluminum-garnet (Er:YAG) lasers, which emit light in the infrared spectrum. The exposed tissue rapidly heats due to the preferential absorption of energy by intracellular water, which leads to vaporization. The wavelength of the Er:YAG laser (2940 nm) is closer to the absorption peak of water (3000 nm) compared to that of the CO 2 laser (10,600 nm). Consequently, during Er:YAG laser applications, almost all energy is absorbed in the epidermis and papillary dermis, yielding superficial ablation with less accompanying thermal tissue damage and thermocoagulation. Contrarily, heat generation and coagulation are prominent features of CO 2 laser applications. Extreme heat generation is avoided during ablative laser surgeries to diminish ominous long-term complications, such as postinflammatory hyperpigmentation and scarring. However, heat generation can be beneficial and/or are required for certain conditions since the thermal effect stimulates collagen production and provides hemostasis. Conventional Er:YAG lasers lead to almost pure ablation with minimal thermal damage; however, coagulation can be acquired to a certain degr","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42731792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.67424
A. Kavak, Ç. Aydoğmuş, Kübra Yılmaz
Address for Correspondence/Yazışma Adresi: Ayşe Kavak MD, Acıbadem Mehmet Ali Aydınlar University, School of Medicine, Department of Dermatology, İstanbul, Turkey Phone: +90 212 404 42 32 E-mail: ayse.kavak1@gmail.com Received/Geliş Tarihi: 04.07.2021 Accepted/Kabul Tarihi: 03.12.2021 ORCID: orcid.org/0000-0002-4679-1181 Cite this article as: Kavak A, Aydoğmuş Ç, Yılmaz K. Dupilumab combined with a short-term narrowband-ultraviolet B phototherapy in a pediatric case of severe atopic dermatitis. Turkderm-Turk Arch Dermatol Venereol 2022;56:39-41 Abstract
通讯地址：Ayşe Kavak医学博士，Acıbadem Mehmet Ali Aydınlar大学医学院皮肤科，土耳其伊斯坦布尔电话：+90 212 404 42 32电子邮件：ayse.kavak1@gmail.com收到/GelişTarihi:2021年7月4日接受/Kabul Tarihi：2021年12月3日ORCID:ORCID.org/0000-0002-4679-1181引用本文为：Kavak A，AydoğmuşÇ，Yılmaz K.Dupilumab联合短期窄带紫外线B光疗法治疗儿童严重特应性皮炎。Turkderm Turk Arch Dermatol Venereol 2022；56:39-41摘要
{"title":"Dupilumab combined with a short-term narrowband- ultraviolet B phototherapy in a pediatric case of severe atopic dermatitis","authors":"A. Kavak, Ç. Aydoğmuş, Kübra Yılmaz","doi":"10.4274/turkderm.galenos.2021.67424","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.67424","url":null,"abstract":"Address for Correspondence/Yazışma Adresi: Ayşe Kavak MD, Acıbadem Mehmet Ali Aydınlar University, School of Medicine, Department of Dermatology, İstanbul, Turkey Phone: +90 212 404 42 32 E-mail: ayse.kavak1@gmail.com Received/Geliş Tarihi: 04.07.2021 Accepted/Kabul Tarihi: 03.12.2021 ORCID: orcid.org/0000-0002-4679-1181 Cite this article as: Kavak A, Aydoğmuş Ç, Yılmaz K. Dupilumab combined with a short-term narrowband-ultraviolet B phototherapy in a pediatric case of severe atopic dermatitis. Turkderm-Turk Arch Dermatol Venereol 2022;56:39-41 Abstract","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47782982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.37650
Münevver Güven, T. Atakul, S. Çelik, M. Yılmaz, B. Demirci
{"title":"The effects of acitretin on ovarian reserve: An experimental study in rats","authors":"Münevver Güven, T. Atakul, S. Çelik, M. Yılmaz, B. Demirci","doi":"10.4274/turkderm.galenos.2021.37650","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.37650","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41406185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-22DOI: 10.4274/turkderm.galenos.2021.29904
T. Ergun, I. Ergenc, Seda Seven, D. Seckin, Elif Cömert Özer, Meryem Aktas, Elif Tükenmez Tigen
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.
{"title":"Drug eruption: A mimicker of Coronavirus disease-2019 rash","authors":"T. Ergun, I. Ergenc, Seda Seven, D. Seckin, Elif Cömert Özer, Meryem Aktas, Elif Tükenmez Tigen","doi":"10.4274/turkderm.galenos.2021.29904","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.29904","url":null,"abstract":"Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections can be associated with several cutaneous lesions, among which maculopapular rash is the most common. A maculopapular rash can also be induced by medications used for Coronavirus disease-2019 (COVID-19) treatment. The distinction between viral rash and drug eruption may be difficult especially in case of several medication use for COVID-19. Thus, this study aimed to describe cutaneous manifestations in six patients with COVID-19 and highlight dues for distinguishing SARS-CoV-2-related rash and drug eruption. Between March and June 2020, 1,492 patients were hospitalized for COVID-19 and treated with hydroxychloroquine in Marmara University Hospital. Among them, six cases were consulted for possible COVID-19-related rash or drug reaction. Hydroxychloroquine was given as monotherapy in one patient. All six patients developed an erythematous, symmetrical, and maculopapular eruption that mainly affected the trunk, axilla, and genitocrural region, 5-21 days after the onset of COVID-19 symptoms. Five patients developed rash in 4-11 days after treatment completion. Pruritus was severe. All were treated with topical corticosteroids and oral antihistamines, which provided partial relief. The resolution of the eruption was typically slow, which took a few weeks. A long period between the COVID-19 symptoms and the eruption, as well as slow recovery, is in favor of drug eruption. The effects of co-existent viral infection, a well-known promoting drug eruption factor, in facilitating adverse drug reaction in patients with COVID-19 needs further observations and research.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47656310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-20DOI: 10.4274/turkderm.galenos.2021.81073
Müge Göre Karaali
{"title":"Isotretinoin induced dysuria: A case report and review of literature about urological effects of isotretinoin","authors":"Müge Göre Karaali","doi":"10.4274/turkderm.galenos.2021.81073","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.81073","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44733268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-20DOI: 10.4274/turkderm.galenos.2021.95680
A. Ünal
{"title":"Evaluation of mean platelet volume and platelet count in patients with hidradenitis suppurativa","authors":"A. Ünal","doi":"10.4274/turkderm.galenos.2021.95680","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.95680","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49216502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-20DOI: 10.4274/turkderm.galenos.2021.77392
Fezal Özdemir, M. Gürel, I. Karaarslan, Vefa Aslı Turgut Erdemir, A. E. Koku Aksu, Ayda Acar
{"title":"In vivo reflectance confocal microscopy terminology in theTurkish language","authors":"Fezal Özdemir, M. Gürel, I. Karaarslan, Vefa Aslı Turgut Erdemir, A. E. Koku Aksu, Ayda Acar","doi":"10.4274/turkderm.galenos.2021.77392","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.77392","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":"11 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41311593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-20DOI: 10.4274/turkderm.galenos.2021.73444
M. K. Taşolar, G. Erfan, Onur Raimoğlu, H. Albayrak, M. Yanık
{"title":"Role of GDF-15 as an inflammatory marker in patients with psoriasis vulgaris","authors":"M. K. Taşolar, G. Erfan, Onur Raimoğlu, H. Albayrak, M. Yanık","doi":"10.4274/turkderm.galenos.2021.73444","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.73444","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42645021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-20DOI: 10.4274/turkderm.galenos.2021.54936
G. Erfan
{"title":"In misleading histories: Key role of dermoscopy","authors":"G. Erfan","doi":"10.4274/turkderm.galenos.2021.54936","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2021.54936","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43316075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：